RxDoctor Payments Data

Thomas Liu, MD

Gastroenterology · Exeter, NHNPI 1245270255

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 35.6% of the total. Reporting peaked in 2019 at $771 and has fallen 72.6% since, to $211 in 2024.

$1,758in general payments, 2019–2025

Across 94 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$625
  • AbbVie$329
  • Johnson & Johnson$139
  • Takeda Pharmaceuticals U.S.A., Inc.$115
  • Ironwood Pharmaceuticals, Inc$89
  • Pfizer$47
  • plus $413 from 15 others

What the payments were for

  • Food & beverage$1,758100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,758 in reported general payments places this provider in the 65th percentile of 91 gastroenterology providers in New Hampshire.

See all gastroenterology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$33,556
Medicare patients
190
Services billed
262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide16$13,734
Omeprazole164$3,220
Lubiprostone17$3,021
Esomeprazole Magnesium12$1,820
Pantoprazole Sodium20$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$329$13,73416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 91 gastroenterology providers in New Hampshire.

Other gastroenterology in Exeter

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →